BCL-2 dependence has been demonstrated in primary AML blasts harbouring IDH mutations, and improved anti-leukaemic activity was observed in a murine IDH2 mutant model of AML by combining venetoclax with enasidenib [61,82]. Here, IDH1 is linked to acute myeloid leukemia.